Phil NewmanEditor-in-Chief
Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.
In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
![Ozone therapy recently hit the headlines as one of the many treatment options being examined to mitigate the effects of COVID-19 [1], but it is also showing great promise in the treatment of neurodegenerative conditions such as Alzheimer’s and Parkinson's.](https://www.longevity.technology/wp-content/uploads/2020/10/Ozone-therapyW-218x150.jpg "Stopping neurodegeneration in its tracks with ozone therapy")
